J Neurogastroenterol Motil.
2022 Jan;28(1):28-42. 10.5056/jnm21221.
Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea
- Affiliations
-
- 1Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea
- 3Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea
- 4Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jeonbuk National University Medical School and Hospital, Jeonju, Jeollabuk-do, Korea
- 5Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Hallym College of Medicine, Hallym University, Anyang, Gyeonggi-do, Korea
- 6Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Jeollabuk-do, Korea
- 7Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
- 8Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
- 9Institute for Digestive Research, Digestive Disease Center, Soonchunhyang University College of Medicine, Seoul, Korea
- 10Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea
- 11Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
- 12Department of Internal Medicine, Ajou University School of Medicine, Suwon, Gyeonggi-do, Korea
- 13Department of Internal Medicine, Hanyang University School of Medicine, Seoul, Korea
- 14Division of Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaboration Agency, Seoul, Korea
- KMID: 2523781
- DOI: http://doi.org/10.5056/jnm21221
Abstract
- Fecal microbiota transplantation (FMT) is a highly efficacious and safe modality for the treatment of recurrent or refractory Clostridioides difficile infection (CDI), with overall success rates of 90%. Thus, FMT has been widely used for 10 years. The incidence and clinical characteristics of CDI, the main indication for FMT, differ between countries. To date, several guidelines have been published. However, most of them were published in Western countries and therefore cannot represent the Korean national healthcare systems. One of the barriers to performing FMT is a lack of national guidelines. Accordingly, multidisciplinary experts in this field have developed practical guidelines for FMT. The purpose of these guidelines is to aid physicians performing FMT, which can be adapted to treat CDI and other conditions.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Fecal Microbiota Transplantation and the Brain Microbiota in Neurological Diseases
- Clinical Usefulness of Fecal Microbiota Transplantation
- The practice of fecal microbiota transplantation in inflammatory bowel disease
- Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders
- Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?
